Abstract: A suspension formulation for therapeutic use includes a non-aqueous, single-phase vehicle exhibiting viscous fluid characteristics and a particle formulation comprising an erythropoietin receptor agonist dispersed in the vehicle.
Type:
Grant
Filed:
August 1, 2005
Date of Patent:
August 10, 2010
Assignee:
Alza Corporation
Inventors:
Kui Liu, Michael A. Desjardin, Beth L. Hill, Zengji Li
Abstract: A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided.
Abstract: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.
Type:
Application
Filed:
March 2, 2010
Publication date:
June 24, 2010
Applicant:
Alza Corporation
Inventors:
Mahmoud Ameri, Michel J.N. Cormier, Yuh-Fun Maa, Marika Kamberi, Peter E. Daddona
Abstract: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.
Type:
Application
Filed:
July 1, 2009
Publication date:
June 17, 2010
Applicant:
Alza Corporation
Inventors:
Mahmoud Ameri, Michel J.N. Cormier, Yuh-Fun Maa, Peter E. Daddona, Marika Kamberl
Abstract: A transdermal electrotransport drug delivery device having an anode, a cathode and a source of electrical power electrically connected to the anode and the cathode. At least one of the anode and the cathode includes an electrode and a reservoir comprised of a housing composed of a polymeric material and an aqueous medium in contact with the housing. The aqueous medium includes (i) a drug or an electrolyte salt or a mixture thereof, (ii) propylene glycol, and (iii) an antimicrobial agent in an amount sufficient to inhibit microbial growth in the aqueous medium. The propylene glycol prevents the antimicrobial agent from being adsorbed by other materials used in the construction of the delivery device. A process for preparing a transdermal electrotransport drug delivery device is also provided.
Abstract: An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers. In one embodiment, the PTH-based agent is contained in a biocompatible coating that is applied to the microprojection member.
Type:
Application
Filed:
June 8, 2009
Publication date:
May 13, 2010
Applicant:
Alza Corporation
Inventors:
Mahmoud Ameri, Michel J.N. Cormier, Yuh-Fun Maa, Peter E. Daddona, Marika Kamberi
Abstract: An electrotransport device (10) for delivering therapeutic agents includes an adjustable voltage boos multiple controller (100, 200) for boosting the voltage from a power source (102, 202) to a working voltage Vw having a value just sufficient to provide the desired therapeutic current level II through the electrodes (108, 112), at least of which contains the therapeutic agent to be delivered.
Type:
Grant
Filed:
November 30, 2004
Date of Patent:
May 4, 2010
Assignee:
Alza Corporation
Inventors:
Thomas A. Riddle, Larry A. McNichols, John D. Badzinski
Abstract: An electrotransport device for delivering one or more therapeutic agents through the skin includes electrodes for contacting the skin, at least one electrode containing the agent, a power source for generating electrical current (IL) for delivering the agent, a current generating and controlling means and a disabling means for permanently and irreversibly disabling the current. The disabling means may include a timer means, a counter means, or a body parameter sensor and limit comparator to effect permanent disabling. The disabling means may be a permanent transition to a disabled logic state, a permanent discharge of a power supply source, or a permanent diversion of electrotransport current from the electrodes, or a combination of the above.
Type:
Application
Filed:
November 30, 2009
Publication date:
March 25, 2010
Applicant:
ALZA Corporation
Inventors:
Larry A. McNichols, John D. Badzinski, William N. Reining, Gary A. Lattin, Ronald P. Haak, Joseph B. Phipps
Abstract: An electrotransport device for delivering one or more therapeutic agents through the skin includes electrodes for contacting the skin, at least one electrode containing the agent, a power source for generating electrical current (IL) for delivering the agent, a current generating and controlling means and a disabling means for permanently and irreversibly disabling the current. The disabling means may include a timer means, a counter means, or a body parameter sensor and limit comparator to effect permanent disabling. The disabling means may be a permanent transition to a disabled logic state, a permanent discharge of a power supply source, or a permanent diversion of electrotransport current from the electrodes, or a combination of the above.
Type:
Grant
Filed:
January 18, 2006
Date of Patent:
February 9, 2010
Assignee:
ALZA Corporation
Inventors:
Larry A. McNichols, Joseph B. Phipps, Gary A. Lattin, John D. Badzinski, Wiliam N. Reining, Ronald P. Haak
Abstract: The present invention encompasses an improved electrotransport drug delivery device utilizing a hydrophobic modifier to prevent moisture condensation. Use of a hydrophobic modifier increases the hydrophobicity of coated parts of the device, reducing the amount of moisture uptake of the device during storage in a high humidity environment. In a further embodiment, a package of the improved electrotransport drug delivery device is provided. In addition, a method of reducing moisture condensation to an electrical device and a method of preserving an electrical device for an electrotransport drug delivery device are provided.
Type:
Application
Filed:
June 30, 2009
Publication date:
January 7, 2010
Applicant:
ALZA Corporation
Inventors:
Rodney M. Panos, Steven Rabin, Robert K. Lowry, Aimee Raymond, Arthur Jonath
Abstract: A transdermal electrotransport fentanyl delivery system having relatively stable fentanyl flux. The system has a controller that controls a current through a donor reservoir wherein the current is generally changed nonlinearly with time with conductance or resistance as a factor to result in a relatively stable fentanyl flux.
Abstract: Methods of modifying polypeptide drugs in order to enhance their transdermal electrotransport flux are provided. The polypeptide is modified by substituting a histidine residue (His) for one or more glutamine (Gln), threonine (Thr) and/or asparagine (Asn) residue(s). The His for Gln substitution is particularly preferred from the standpoint of retaining biological activity of the parent polypeptide. Compositions containing the modified polypeptide, which are useful for transdermal electrotransport delivery, are also provided.
Abstract: A compound comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-containing ligand through a dithiobenzyl linkage is described.
Abstract: The invention provides an improved electrotransport drug delivery system for analgesic drugs, namely fentanyl and sufentanil. The fentanyl/sufentanil is provided as a water soluble salt (eg, fentanyl hydrochloride) dispersed in a hydrogel formulation for use in an electrotransport device (10). In accordance with one aspect of the invention, the concentration of fentanyl/sufentanil in the donor reservoir (26) solution is above a predetermined minimum concentration, whereby the transdermal electrotransport flux of fentanyl/sufentanil is maintained independent of the concentration of fentanyl/sufentanil in solution. In accordance with a second aspect of the present invention, the donor reservoir (26) of the electrotransport delivery device (10) is comprised of silver and the donor reservoir (26) contains a predetermined “excess” loading of fentanyl/sufentanil halide to prevent silver ion migration with attendant skin discoloration.
Abstract: A conjugate comprised of a hydrophilic polymer covalently yet reversibly linked to a amine-, hydroxy- or carboxyl-containing ligand is described. The resulting conjugate is capable of releasing the parent amine, hydroxy, or carboxyl-containing compound via thiol-mediated cleavage. The system allows for delivery of various amino-, hydroxy-, or carboxy-containing drugs in the form of their thiolytically cleavable macromolecular conjugates.
Abstract: Disclosed are methods of sustained release administration of opioids, including but not limited to hydromorphone and oxycodone, that exhibit improved properties with respect to co-ingestion with aqueous alcohol.
Abstract: The invention provides for a formulation for coating one or more microprojections which reduces or minimizes the loss of counterions from the coating in order to achieve a pH-stabilized formulation.
Type:
Grant
Filed:
June 29, 2004
Date of Patent:
August 25, 2009
Assignee:
Alza Corporation
Inventors:
Mahmoud Ameri, WeiQi Lin, Michel J. N. Cormier, Yuh-Fun Maa
Abstract: A method of increasing the delivery efficiency of an agent through a body surface by electrotransport is disclosed wherein the electrotransport current is applied for durations at a higher current density values followed by durations of lower current density values wherein the higher current density applications transform the body surface to an enhanced, non-transitory agent delivery efficiency state.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
August 11, 2009
Assignee:
Alza Corporation
Inventors:
J. Bradley Phipps, Gary A. Lattin, Ronald P. Haak, Suneel Gupta, Felix Theeuwes
Abstract: An Apparatus and method are provided for selectively applying an agent-containing liquid coating to extremely tiny skin piercing microprojections (10). The coating solution is applied to the skin piercing microprojections (10) using a coating technique which selectively coats only the skin piercing microprojections (10) and not to substrate (12) from which the microprojections (10) extend, and the dried. The coating method includes providing an agent-containing coating liquid and conveying the liquid to a liquid holding surface having a coating transfer region. The depth of the coating liquid at the coating transfer region is precisely controlled. The microprojections are then immersed to a predetermined level in the coating liquid. The liquid that coats the microprojections (10) is then dried to form a solid agent-containing coating on the microprojections (10).
Type:
Application
Filed:
October 8, 2008
Publication date:
July 23, 2009
Applicant:
ALZA CORPORATION
Inventors:
Joseph C. Trautman, Cedric T. Wright, Michel J. N. Cormier